Theresa Kowalski-Dobson

Theresa Kowalski-Dobson

Auto-generated profile, based on publicly available information

Theresa Kowalski-Dobson

Department of Epidemiology, School of Public Health, University of Michigan , Ann Arbor, Michigan , USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
HMHannah E. Maier
Hannah E. Maier
TKTheresa Kowalski-Dobson
Theresa Kowalski-Dobson
AEAshley Eckard
Ashley Eckard
CGCarmen Gherasim
Carmen Gherasim
DMDavid Manthei
David Manthei
AGAubree Gordon
Aubree Gordon
The impact of vaccination prior to infection on postacute sequelae of coronavirus disease 2019 (COVID-19, PASC), also known as long COVID, remains unclear. Here we assess the protective effect of vaccination on long COVID in a community-based setting. The Immunity Associated with SARS-CoV-2 (IASO) study is an ongoing prospective cohort of working adults that began in October 2020. Participants are actively followed for severe acute respiratory syndrome coronavirus 2 infection. We compared the prevalence of symptoms and symptom severity in vaccinated compared to unvaccinated cases. Our primary definition of long COVID was the presence of symptoms at 90 days postinfection; 30 days postinfection was also examined. Overall, by 90 days postinfection, 13% of cases had long COVID, with 27% of unvaccinated cases and 8% of vaccinated cases reporting long COVID (relative risk [RR], 0.31 [95% confidence interval {CI}, .22–.42]). Vaccination was also associated with significantly lower average severity scores at all timepoints (eg, relative severity at 90 days postinfection: −2.70 [95% CI, −1.68 to −3.73]). In the pre-Omicron era, 28% of unvaccinated cases and 18% of vaccinated cases reported long COVID (P = .07), and vaccinated cases reported less severe symptoms including less difficulty breathing (P = .01; 90-day RR, 0.07). Vaccinated cases had lower prevalence of long COVID and reduced symptom severity.

31 January 2022 in Cell Reports
Verified
Journal Article
Open access
PHPeter J. Halfmann
Peter J. Halfmann
MKMakoto Kuroda
Makoto Kuroda
TATammy Armbrust
Tammy Armbrust
MAMolly Accola
Molly Accola
RVRiccardo Valdez
Riccardo Valdez
YKYoshihiro Kawaoka
Yoshihiro Kawaoka
The emergence of the SARS-CoV-2 Delta variant (B.1.617.2) raises concerns about potential reduced sensitivity of the virus to antibody neutralization and subsequent vaccine breakthrough infections. Here, we use a live virus neutralization assay with sera from Pfizer- and Moderna-vaccinated individuals to examine neutralizing antibody titers against SARS-CoV-2 and observe a 3.9- and 2.7-fold reduction, respectively, in neutralizing antibody titers against the Delta variant compared with an early isolate bearing only a D614G substitution in its spike protein. We observe similar reduced sensitivity with sera from hamsters that were previously infected with an early isolate of SARS-CoV-2. Despite this reduction in neutralizing antibody titers against the Delta variant, hamsters previously infected (up to 15 months earlier) with an early isolate are protected from infection with the Delta variant, suggesting that the immune response to the first infection is sufficient to provide protection against subsequent infection with the Delta variant.

3 September 2018 in Health Promotion Practice
Verified
Journal Article
Open access
PDF file
LLLaurie Lachance
Laurie Lachance
TKTheresa Kowalski-Dobson
Theresa Kowalski-Dobson
MQMartha Quinn
Martha Quinn